Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gubra ASHAM:PI3 -1.34%53 Earnings Yield (Joel Greenblatt) % is 28.90% as of Dec. 2025. GuruFocus rates HAM:PI3 with a GF Score™ of 53/100 and a GF Value™ of €388.86 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,329 Biotechnology companies, Gubra AS ranks better than 98.27% on this metric.
Gubra AS's Enterprise Value for the quarter that ended in Dec. 2025 was €1,011.9 Mil.
Gubra AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €289.7 Mil. Gubra AS's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 28.90%.
The historical rank and industry rank for Gubra AS's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
HAM:PI3'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2.65 Med: -0.42 Max: 50.47
Current: 44.77
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Gubra AS was 50.47%. The lowest was -2.65%. And the median was -0.42%.
HAM:PI3's Earnings Yield (Joel Greenblatt) % is ranked better than 98.27% of 1329
companies
in the Biotechnology industry
Industry Median: -10.17
vs HAM:PI3: 44.77
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Gubra AS's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Gubra AS (HAM:PI3) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Gubra AS Earnings Yield (Joel Greenblatt) % Related Terms
Gubra AS Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Gubra AS's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gubra AS's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Gubra AS's Earnings Yield (Joel Greenblatt) % falls into.
Gubra AS Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Gubra ASs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 28.90% mean?
Gubra AS (HAM:PI3) has a Earnings Yield (Joel Greenblatt) % of 28.90% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Gubra AS and its competitors. According to the industry distribution chart, Gubra AS ranks #23 out of 1329 companies in the Biotechnology industry, placing it in the top 1.7%.
Is Gubra AS's Earnings Yield (Joel Greenblatt) % too high?
Gubra AS's current Earnings Yield (Joel Greenblatt) % is 28.90%. Based on the distribution chart, Gubra AS ranks #23 out of 1329 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gubra AS has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #23 out of 1329 companies for Earnings Yield (Joel Greenblatt) %. This places Gubra AS in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Gubra AS and its competitors. Gubra AS's current Earnings Yield (Joel Greenblatt) % is 28.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (HAM:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €388.86, compared to a current price of €45.70 — trading 88.2% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 28.90%. Gubra AS's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Gubra AS (HAM:PI3), the current Earnings Yield (Joel Greenblatt) % is 28.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (HAM:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €45.70 is trading 88.2% below its estimated GF Value™ of €388.86.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for HAM:PI3:
Earnings Yield (Joel Greenblatt) %: 28.90%
GF Value™: €388.86 vs. price of €45.70 (88.2% below fair value)
No single metric tells the full story. See the HAM:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
53GF Score
Get the complete analysis for HAM:PI3
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:PI3 has been successfully added to your 
